Summit Therapeutics Inc.
SMMT
$18.95
$0.291.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 839.20% | 824.62% | 757.15% | 870.52% | 84.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 419.33% | 418.71% | 414.97% | 428.37% | 104.95% |
| Operating Income | -419.33% | -418.71% | -414.97% | -428.37% | -104.95% |
| Income Before Tax | -400.96% | -387.81% | -368.59% | -361.42% | -107.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -400.96% | -387.81% | -368.59% | -361.42% | -107.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -400.96% | -387.81% | -368.59% | -361.42% | -107.50% |
| EBIT | -419.33% | -418.71% | -414.97% | -428.37% | -104.95% |
| EBITDA | -419.45% | -418.86% | -415.17% | -428.70% | -105.11% |
| EPS Basic | -384.71% | -369.70% | -348.63% | -338.19% | -99.70% |
| Normalized Basic EPS | -417.50% | -404.19% | -385.73% | -382.53% | -86.97% |
| EPS Diluted | -358.78% | -350.89% | -341.11% | -335.38% | -110.98% |
| Normalized Diluted EPS | -417.50% | -404.19% | -385.73% | -382.53% | -86.97% |
| Average Basic Shares Outstanding | 4.05% | 4.06% | 4.39% | 4.87% | 4.01% |
| Average Diluted Shares Outstanding | 4.05% | 4.06% | 4.39% | 4.87% | 4.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |